A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 15 May 2025
At a glance
- Drugs FG 3246 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors FibroGen
Most Recent Events
- 12 May 2025 According to a FibroGen media release, company to anticipate initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC in the third quarter of 2025.
- 02 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 30 Apr 2025.
- 28 Mar 2025 According to a FibroGen media release, company anticipate topline results from the Phase 2 portion of the study anticipated in 2H 2025